as on February 20, 2026 at 7:59 am IST
Day's Low
Day's High
9.11%
Downside
0.93%
Upside
52 Week's Low
52 Week's High
68.69%
Downside
72.84%
Upside
Check Replimune Group Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$663.9M
EPS (TTM)
-3.072
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
0PEG Ratio
0EBITDA
-318.9M
Revenue (TTM)
-
Profit Margin
0.00%
Return On Equity TTM
-90.88%
Compare market cap, revenue, PE, and other key metrics of Replimune Group Inc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $663.9M | -77.45% | NA | 0.00% |
The Replimune Group Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Replimune Group Inc investment value today
Current value as on today
₹64,882
Returns
Returns from Replimune Group Inc Stock
Dollar Returns*
₹5,064 (+5.06%)
Based on 15 analysts
93.33%
Buy
6.67%
Hold
0.00%
Sell
Based on 15 analysts, 93.33% of analysts recommend a 'BUY' rating for Replimune Group Inc. Average target price of $12.86
Get share price movements and forecasts by analysts on Replimune Group Inc.
What analysts predicted
33.44%UPSIDE
Target Price
$12.86
Current Price
$8.56
Analyzed by
15 Analysts
Target
$12.86
Replimune Group Inc target price $12.86, a slight upside of 33.44% compared to current price of $8.56. According to 15 analysts rating.
Search interest for Replimune Group Inc Stock has decreased by -2% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 20 October
Mon, 06:49 PM
-Replimune's stock rises 105% after FDA accepts resubmission for RP1 therapy in advanced melanoma, with a decision due by April 2026.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Promoter Holding Up
![]()
Promoters have increased holdings from 68.55% to 68.64% in Dec 2025 quarter
Price Rise
![]()
In the last 7 days, REPL stock has moved up by 7.3%
Against Peers
![]()
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 52.8% return, outperforming this stock by 118.4%
Against Peers
![]()
In the last 3 years, eClerx Services Ltd has given 149.4% return, outperforming this stock by 187.6%
Against Peers
![]()
In the last 1 year, Beone Medicines Ltd has given 45.2% return, outperforming this stock by 85.5%
Against Peers
![]()
In the last 1 year, One 97 Communications Ltd has given 51.6% return, outperforming this stock by 111.9%
Retail Holding Down
![]()
Retail Investor have decreased holdings from 31.34% to 31.24% in Dec 2025 quarter
Price Dip
![]()
In the last 7 days, REPL stock has moved down by -7.0%
Profit Down
![]()
Netprofit is down for the last 3 quarters, 2.49 Cr → -1.38 Cr (in ₹), with an average decrease of 153.6% per quarter
Revenue Fall
![]()
Revenue is down for the last 2 quarters, 22.22 Cr → 21.46 Cr (in ₹), with an average decrease of 3.4% per quarter
| Organisation | Replimune Group Inc |
| Headquarters | 500 Unicorn Park Drive, Woburn, MA, United States, 01801 |
| Industry | Health Technology |
| CEO | Dr. Sushil Patel Ph.D. |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Mr. Paul Bullock | Chief Manufacturing Officer & Framingham Site Head |
Ms. Nina Aragam | Senior Vice President of Portfolio Strategy & Program Management |
Ms. Emily Luisa Hill | Chief Financial Officer |
Mr. Camilo Garcia M.A., M.B.A. | Chief Human Resource Officer |
Mr. Christopher Sarchi | Chief Commercial Officer |
Mr. Andrew Schwendenman | Chief Accounting Officer & Treasurer |
Mr. Shawn Glidden J.D. | Senior VP & General Counsel |
Dr. Sushil Patel Ph.D. | CEO & Director |
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer |
Mr. Philip Astley-Sparke F.S.A. | Executive Chairman |
Replimune Group Inc share price today is $8.56 as on at the close of the market. Replimune Group Inc share today touched a day high of $8.64 and a low of $7.78.
Replimune Group Inc share touched a 52 week high of $14.8 on and a 52 week low of $2.68 on . Replimune Group Inc stock price today i.e. is closed at $8.56,which is 42.14% down from its 52 week high and 219.40% up from its 52 week low.
Replimune Group Inc market capitalisation is $0.00T as on .
Indian investors can start investing in Replimune Group Inc (REPL) shares with as little as ₹90.973 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹909.73 in Replimune Group Inc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Replimune Group Inc share’s latest price of $8.56 as on February 20, 2026 at 2:29 am IST, you will get 1.1682 shares of Replimune Group Inc. Learn more about
fractional shares .
Replimune Group Inc stock has given -77.45% share price returns and 25.1% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?